Eisai's Fycompa falls at German HTA comparator hurdle, like GSK's Trobalt
This article was originally published in Scrip
Comparator issues that proved troublesome for GlaxoSmithKline's antiepileptic Trobalt (retigabine) in Germany are now causing problems for Eisai's own antiepileptic Fycompa (perampanel). IQWiG, the body that carries out the preliminary scientific assessment for Germany's AMNOG early benefit assessments, said that Eisai's drug offers no additional benefit over comparators because it did not submit any relevant data lamotrigine or topiramate.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.